Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of preoperative cetuximab-based chemotherapy for resectable or potentially resectable colorectal liver metastases
2013-002347-28Phase 2Terminated
- Sponsor
- ACROSS: Associació Catalana per a la Recerca Oncològica i les seves implicacions sanità ries i Socials
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer liver metastasis (CRLM), sponsored by ACROSS: Associació Catalana per a la Recerca Oncològica i les seves implicacions sanità ries i Socials. Primary endpoint: Pathological response in resected liver metastases. Started Jul 2013; status: terminated.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2013-002347-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002347-28.